» Articles » PMID: 30186819

-Catenin Regulation in Sporadic Colorectal Carcinogenesis: Not As Simple As APC

Overview
Specialty Gastroenterology
Date 2018 Sep 7
PMID 30186819
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The wnt/APC/-catenin pathway is a critical initiator in colorectal carcinogenesis in both hereditary and sporadic colorectal cancer (CRC). The progression of this process remains incompletely understood, although inflammation is pivotal. Drivers of inflammation are elevated in malignant tissue and have been shown to regulate -catenin expression. Interleukin-17A (IL-17A) is protumorigenic at elevated levels via COX-2 stimulation. Elevated peroxisome proliferator-activated receptor (PPAR) expression has reduced risk of carcinogenesis and good overall prognosis in established CRC. Activation of PPAR has inhibitory effect on -catenin.

Methods: Using qPCR and IHC, we compared -catenin, PPAR, COX-2, and IL-17A in the colonic mucosa of patients with sporadic CRC, inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS), against a normal control population.

Results: -catenin mRNA and protein expression progressively increased from the Normal group, through IBS and IBD reaching statistical significance in CRC. COX-2 mRNA levels increased similarly with statistical significance in IBD and CRC. However, COX-2 protein expression was inverted with significant expression in the Normal and IBS groups and reduced levels in IBD and CRC. PPAR mRNA expression was unchanged in IBD and CRC but was significantly elevated in the IBS. IL-17A mRNA was significantly reduced in IBS and CRC but unchanged in IBD. There were no differences in all parameters tested in the Normal and IBS groups.

Conclusion: -catenin is confirmed as a major driver of colorectal carcinogenesis but is controlled by many more players other than APC. Elevated levels of PPAR may have an anticarcinogenic effect. The role of COX-2 expression, especially its posttranscriptional regulation in colorectal cancer, needs further elucidation.

Citing Articles

Erlotinib suppresses tumorigenesis in a mouse model of colitis-associated cancer.

Liu M, Zhong X, Krishnachaitanya S, Ou R, Dashwood R, Powell D Biomed Pharmacother. 2024; 175:116580.

PMID: 38723513 PMC: 11883833. DOI: 10.1016/j.biopha.2024.116580.


Serum Cytokine and miRNA Levels Are Differently Expressed in Right- and Left-Sided Colon Cancer.

De Nunzio V, Donghia R, Pesole P, Coletta S, Calo N, Notarnicola M J Clin Med. 2023; 12(18).

PMID: 37762927 PMC: 10532301. DOI: 10.3390/jcm12185986.


Novel read through agent: ZKN-0013 demonstrates efficacy in APC model of familial adenomatous polyposis.

Graf M, Apte S, Terzo E, Padhye S, Shi S, Cox M J Mol Med (Berl). 2023; 101(4):375-385.

PMID: 36808265 DOI: 10.1007/s00109-023-02291-x.


Wnt signaling in colorectal cancer: pathogenic role and therapeutic target.

Zhao H, Ming T, Tang S, Ren S, Yang H, Liu M Mol Cancer. 2022; 21(1):144.

PMID: 35836256 PMC: 9281132. DOI: 10.1186/s12943-022-01616-7.


Validation of Novel Molecular Imaging Targets Identified by Functional Genomic mRNA Profiling to Detect Dysplasia in Barrett's Esophagus.

Zhao X, Gabriels R, Hooghiemstra W, Koller M, Meersma G, Buist-Homan M Cancers (Basel). 2022; 14(10).

PMID: 35626066 PMC: 9139936. DOI: 10.3390/cancers14102462.


References
1.
Xiong B, Sun T, Hu W, Cheng F, Mao M, Zhou Y . Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance. World J Gastroenterol. 2005; 11(8):1105-8. PMC: 4250698. DOI: 10.3748/wjg.v11.i8.1105. View

2.
Eisinger A, Nadauld L, Shelton D, Peterson P, Phelps R, Chidester S . The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid. J Biol Chem. 2006; 281(29):20474-82. DOI: 10.1074/jbc.M602859200. View

3.
Wang D, DuBois R . The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene. 2009; 29(6):781-8. PMC: 3181054. DOI: 10.1038/onc.2009.421. View

4.
Shen D, Deng C, Zhang M . Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells. Postgrad Med J. 2007; 83(980):414-9. PMC: 2600042. DOI: 10.1136/pmj.2006.052761. View

5.
Ogino S, Shima K, Baba Y, Nosho K, Irahara N, Kure S . Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology. 2009; 136(4):1242-50. PMC: 2663601. DOI: 10.1053/j.gastro.2008.12.048. View